Poor
Not Aligned
Patient Risk:
Medium
Summary
The response includes multiple dosing schedule details (induction duration, number of treatments, transition timing, and maintenance frequency) that are not supported by the provided label excerpts. While safety topics (sedation/dissociation/respiratory depression) and post-administration monitoring duration are supported, the regimen specifics are largely unverified from the supplied text.
Category Scores
Accurate Statements
Spravato treats treatment-resistant depression (TRD) in adults when combined with an oral antidepressant.
Section 1 (Indications and Usage): TRD in adults as monotherapy or in conjunction with an oral antidepressant.
Patients receive 1-hour monitoring afterward.
Not supported by the provided label excerpts; monitoring required is at least 2 hours (Boxed Warning; Section 2.5).
Spravato administrations are given under medical supervision.
Section 2.5 and Boxed Warning indicate monitoring by a healthcare provider during/after administration.
Spravato dosing shifts after the induction period and changes frequency based on response.
Directionally consistent with maintenance concepts, but the specific schedule details provided are not supported by the excerpts provided.
Unsupported Statements
The FDA-approved dosing regimen for Spravato includes an induction phase followed by maintenance.
The provided excerpts do not include the induction/maintenance regimen structure.
The Spravato induction phase lasts 4 weeks.
Not supported by the provided label excerpts.
Spravato induction uses twice-weekly dosing.
Not supported by the provided label excerpts.
The Spravato induction phase totals 8 treatments.
Not supported by the provided label excerpts.
Each Spravato session involves 2 nasal sprays.
Not supported by the provided dosing regimen excerpts; the only provided product-strength excerpt states each device delivers two sprays total 28 mg, but the session/number-of-devices statement is not explicitly tied to a session regimen.
Each nasal spray device contains 28 mg.
Label excerpt states 28 mg esketamine per device and that each device delivers two sprays containing total 28 mg; however the statement as phrased is potentially conflating per-spray vs per-device and is not explicitly confirmed for 'each nasal spray device contains 28 mg' as a device definition tied to the session regimen. (Section 3 supports '28 mg esketamine per device'.)
The total dose per administration is up to 84 mg.
Not supported by the provided label excerpts.
Patients receive 1-hour monitoring afterward.
Contradicted by Boxed Warning and Section 2.5 (at least 2 hours).
After 4 weeks (8 doses) in the induction phase, dosing shifts to once-weekly for week 5, then every 2 weeks or weekly based on response.
Not supported by the provided label excerpts.
For responders, remission often occurs by week 4.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Patients receive 1-hour monitoring afterward.
Label Reference
Boxed Warning: monitored for at least 2 hours at each treatment session; Section 2.5: observe the patient for at least 2 hours until safe to leave.
Important Omissions
Post-administration monitoring duration should be 'at least 2 hours' with an assessment for clinical stability before leaving the healthcare setting.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
An explicit contradiction exists regarding monitoring duration (1 hour stated vs at least 2 hours required). Several dosing schedule specifics are unsupported by the provided label text, which could lead to regimen misrepresentation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Monitoring duration is contradicted (1 hour vs at least 2 hours). Multiple induction/maintenance regimen specifics are not supported by the provided label excerpts.
Suggested Improvement
Replace 1-hour monitoring with 'at least 2 hours' and remove or qualify induction/maintenance schedule details (4 weeks, twice-weekly, 8 treatments, week-5 once-weekly, and every-2-weeks/weekly) unless supported by the provided label sections. Limit dosing-form/strength statements to what is explicitly supported (e.g., 28 mg per device delivers two sprays total 28 mg).